Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 57

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 57
---
 no operations and nominal assets consisting almost entirely of cash.

Iris’s Class A Common Stock is currently trading on the OTC Pink Marketplace under the symbol “IRAA”. Iris’s Redeemable Warrants are currently trading on the OTC Pink Marketplace under the symbol “IRAAW”. Additionally, shares of Iris’s Class A Common Stock and Iris’s Redeemable Warrants trade as Units consisting of one share of Class A Common Stock and one-fourth of one Redeemable Warrant, and are trading on the OTC Pink Marketplace under the symbol “IRAAU” (the “Units”). The Units will automatically separate into their component securities upon consummation of the Business Combination and those component securities will be converted into ParentCo securities and, as a result, Class A Common Stock, Redeemable Warrants, and the Units will no longer trade as independent securities.

The mailing address of Iris’s principal executive office is 3rd Floor Zephyr House, 122 Mary Street, George Town, PO Box 10085, Grand Cayman, KY1-1001, Cayman Islands, and its telephone number is 971 4 3966949.

#### IRIS PARENTCO HOLDING CORP.
ParentCo, a Delaware corporation, was formed on November 23, 2022 to consummate the Business Combination. Following the Transactions, ParentCo will serve as the publicly traded holding company for Liminatus. ParentCo will apply to list its common stock and warrants on the Nasdaq Global Market under the market value standard, under the symbols “LIMN” and “LIMNW,” respectively, upon the closing of the Business Combination. At the Effective Time, we expect ParentCo will satisfy all of the initial listing requirements under the market value standard; however, we currently do not meet the Round Lot Requirement. We have engaged a securities market advisory firm to assist with obtaining the requisite number of round lot stockholders to satisfy the Round Lot Requirement before the Business Combination is consummated.

The financial statements of ParentCo have been omitted because this entity has no assets, has not commenced operations and has not engaged in any business or other activities except in connection with its formation. ParentCo does not have any contingent liabilities or commitments.

#### LIMINATUS PHARMA, LLC
Liminatus, a Delaware limited liability company, is a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies formed on April 12, 2018. In the Business